About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Glofitamab in Chinese Patients With R/R DLBCL | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT06481826

Glofitamab in Chinese Patients With R/R DLBCL

This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more...

Lead sponsor: Peking Union Medical College Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Jing Ruan

CONTACT

+8615201435860 15201435860@163.com

Sponsors

Lead Sponsor

Peking Union Medical College Hospital

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Histologically-confirmed DLBCL
•2. Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy
•3. Participants must have measurable disease

Exclusion Criteria

•1. Pregnancy or breastfeeding
•2. Patient with known active infection, or reactivation of a latent infection
•3. Patient with active autoimmune disease or immune deficiency
•4. severe organ failure：LVEF\<40%；DLCO\<40%；eGFR\<30ml/min；Bilirubin≥3ULN
•5. Patients who are dependent on the sponsor, the investigator or the trial site

Related studies

RECRUITINGPhase 2

DALY II Japan/MB-CART2019.1 for DLBCL

NCT07288879 · DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy

RECRUITINGPhase 2

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

NCT07255963 · DLBCL - Diffuse Large B Cell Lymphoma

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

NCT05940272 · Lymphoma, B-Cell, Lymphoma, and more

RECRUITINGPhase 2

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

NCT06151080 · DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma

Real-World Study of DLBCL With Different Genetic Subtypes

NCT06026488 · DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 1, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment20

Start dateJan 2024

Last updatedJul 1, 2024

Condition

DLBCL - Diffuse Large B Cell Lymphoma

Locations shown

Peking Union Medical College Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions